SANOFI - Sanofi India Ltd Share Price

Management's outlook for Sanofi India reflects a focus on sustainable and profitable growth following significant transformations in the business model, particularly in the diabetes segment. The key points from management include:

1. Financial Performance: In 2025, net sales reached INR 1,511 crores for the domestic market, with diabetes contributing approximately half of that figure. The company reported a consistent growth of 11% in its diabetes segment for the fourth quarter, with insulin overall showing a growth of 6% for the full year.

2. Profitability: For financial year 2025, profit before tax showed an increase of 1%. Operating expenses saw a reduction of 17% for both the quarter and the year, reflecting improved operational efficiency.

3. Partnership Dynamics: There was a reported decline of 2% in the partnership segment year-over-year due to stock movements and agreement-related adjustments. The partnership sales for the fourth quarter were INR 153 crores compared to INR 200 crores in the previous quarter, driven by inventory fluctuations.

4. Growth Expectations: Management expects stabilization in partnership growth towards the end of 2026, with anticipated benefits from stock replenishments and a focus on Tier 2 and Tier 3 market expansions.

5. Market Share and Innovations: The management emphasized the potential for diabetes treatments, particularly with Soliqua and Toujeo, to leverage the ongoing market shift toward GLP-1 therapies. There is an ongoing focus on maximizing the diabetes portfolio prior to exploring additional therapeutic areas.

6. Future Developments: Soliqua is seen as a critical product with the potential to capture a unique market share in both premix and basal insulin therapies, with no new product launches planned for 2026.

7. Dividend Proposal: The board has proposed a 5% increase in dividends for shareholders, bringing the dividend per share to INR 123, indicating a commitment to returning value to investors.

Overall, the management's outlook highlights a commitment to continue navigating the complexities post-transformation while positioning itself for future growth.

Here's a detailed summary of the major questions and their respective answers from the Q&A session of the Sanofi India earnings call on February 26, 2026:

Q1: Rajakumar Vaidyanathan: "What is happening with partnership sales, and why is there a drop of 13% year-on-year? Additionally, there's significant Q3 to Q4 fluctuation from INR 200 crores to INR 153 crores. Can you clarify?"
A1: "The partnership sales are stabilizing. The Q4 drop was primarily due to stock stabilization and replenishment requirements, along with a frozen period during new partnerships. Additional discounts from competition in some accounts also affected.

Q2: Rajakumar Vaidyanathan: "Can we consider the current quarter partnership number as a steady state number for 2026?"
A2: "Fluctuations will persist in 2026. By the end of the year, we expect stabilization in partnerships. However, no definitive forward-looking figures can be provided."

Q3: Vishal Manchanda: "Could you share the end market growth for the partnered portfolio?"
A3: "Excluding OADs, the CV portfolio had low single-digit growth. In contrast, OAD growth was higher single-digit. Overall, we project single-digit growth moving forward."

Q4: Vishal Manchanda: "What impact do you foresee regarding pricing for the partnered portfolio?"
A4: "For NLEM products, pricing will follow WPI growth. For other products, price increases may be up to 10%, depending on market conditions."

Q5: Vishal Manchanda: "How do you intend to scale the diabetes business? Any additional products?"
A5: "We aim to maximize the potential of our existing portfolio first. Soliqua's growth alongside GLP-1 is vital, with plans to expand Toujeo further in public sectors."

Q6: Vipul Shah: "Is Sanofi India considering diversifying into other therapeutic areas?"
A6: "Our focus is primarily on diabetes and partnering within existing frameworks. Any future diversification will depend on synergy with current portfolios and market conditions."

Q7: Avani Gadia: "Why are the results declining year-on-year?"
A7: "While there's a +1% profit before tax and +4% post-tax, the transformation impacts growth visibility. The demerger and partnership agreements have altered financial landscapes."

Q8: Avani Gadia: "What are the upcoming products for Sanofi India in 2026?"
A8: "There are no new product launches planned for 2026. Our focus will be on leveraging Soliqua and Toujeo's expansion."

Q9: Lakshmi Narayana: "What caused the 8-quarter low in EBITDA margins?"
A9: "The decline in margins was primarily due to periodic fluctuations rather than a loss in diabetes and partnership segments."

Q10: Manish: "Can you elaborate on the diabetes segment's performance and if growth could exceed expectations?"
A10: "Diabetes is currently growing at +6%, and without disruption from partnerships, we could see double-digit growth."

Q11: Lakshmi Narayana: "Did Lantus face any availability issues recently?"
A11: "We had adequate stock and continuity for Lantus. Any perceived disruption was likely due to logistics."

This summary retains the key details and figures while condensing the information to fit within the requested character limits.